http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102641501-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_08dde60e3e0ca1e6ffaa5143e5c8477a |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2012-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe06adf683f41e5bc189b29f3e663614 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c46e19db6770fde5c6872bd68b90bdfd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4cf729be98645d31f6694f90565d58e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_859d14326d241508a84acee3d5e77655 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9dc8320c809261fa2f193c18ffbb559 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_730782e805451c51fa2d39476c97aec0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68380454fb385f780aac58b9fba55287 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fab986cd9e522ef59b7cbf405c4542ec |
| publicationDate | 2013-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102641501-B |
| titleOfInvention | Application of NALP3-ASC inflammation complex and activator inhibitor thereof in terms of preparation of medicines for treating prion diseases |
| abstract | The invention discloses application of an NALP3-ASC inflammation complex and an activator inhibitor thereof in terms of preparation of medicines for treating prion diseases. Experiments show that prion infects microgliacyte, NALP3-ASC inflammation complex enhanced caspase-1 and IL-1beta activation are formed. The inflammation complex NALP3 inhibitor can suppress NALP3 and ASC expression, and thensuppresses activation and release of the caspase-1 and IL-1beta. The invention provides the application of the NALP3-ASC inflammation complex inhibitor for screening medicines for treating the prion diseases, by means of cell co-stimulation for a sample to be detected and the prion, total RNA (ribonucleic acid) of treated cells is extracted, NALP3 and ASC are detected by a qPCR (quantitative polymerase chain reaction) method, expression suppression conditions of the sample to mRNA (messenger ribonucleic acid) of the NALP3 and the ASC are judged according to PCR (polymerase chain reaction) amplification results, accordingly medicines for resisting Prion diseases are screened out, and effects of preventing, treating or controlling the prion diseases are realized. |
| priorityDate | 2012-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 110.